TRACING THE VIRUS

AESKU.GROUP offers now six new quantitative AESKULISA SARS-CoV-2 tests. Fast, reliable and easy to automate.Read more

AESKULISA SARS-CoV-2 IgM

Serves for determination of a first specific reaction of the immune system. Our tests are quantitative immunoassays for the demonstration of human IgM antibodies in serum or plasma.Read more

AESKULISA SARS-CoV-2 IgA

Assists in the detection of acute infections. Our tests are quantitative immunoassays for the demonstration of human IgA antibodies in serum or plasma.Read more

AESKULISA SARS-CoV-2 IgG

Serves for confirmation of pathogen contact and supports in immune status determination. Our tests are quantitative immunoassays for the demonstration of human IgG antibodies in serum or plasma.Read more

MEET US AT

Due to the actual situation, we are currently refraining from participating in trade fairs!Find out more about….

In the current situation, it is hardly necessary to argue about the urgent need for an effective and robust vaccine to treat COVID-19, because our society and humanity itself are in a state of emergency. However, not only a vaccine is urgently needed, but the success of vaccination must also be verified using quantitative tests. Quantitative tests react to neutralizing antibodies, i.e., antibodies responding to a pathogen and breaking it down, make it possible to determine the success of an immune response and a vaccination in everyday practice.

For the determination of an immune reaction, the examination of immunoglobulins, so-called antibodies, has been established for years. Since protein structures on the surface of a pathogen (bacterium, virus) are specific, i.e., unique for individual structures, the immune system forms the appropriate antibody; it is possible to examine different antibodies for confirmation and infection. In the case of SARS-CoV-2 viruses, the nucleocapsid protein (N) and the spike protein (S1) are suitable.

AESKU offers six different immunoassays:

AESKULISA® SARS-CoV-2 NP IgM/ IgA / IgG

AESKULISA® SARS-CoV-2 NP IgA, IgG, and IgM tests are qualitative and quantitative immunoassays for the detection of human IgM, IgA, and IgG antibodies in serum or plasma directed against SARS-CoV-2 in highly conserved nucleocapsid protein (NP). The nucleocapsid protein is very reactive and stimulates a strong immune response. This potent immune response provides a very sensitive detection of antibodies, which allows a clear differentiation between positive and negative samples.

They are, therefore, ideal for IgM, IgG, and IgA detection for screening and diagnosis. Due to the high sensitivity and the strong conservation of the nucleocapsid protein in the coronavirus family, the risk of cross-reaction with antibodies against SARS-CoV-1 is increased. Since antibodies against the nucleocapsid protein have no neutralizing effect, they are not suitable for determining the immune status, the so-called antibody titer.

Table 1: Sensitivity and specificity of AESKULISA® SARS-CoV-2 NP IgA and IgG immunoassays were assessed by the analysis of 76 serum samples from healthy blood donors (2018) and 20 individuals with clinically confirmed COVID19 using the clinical findings as a reference.

AESKULISA® SARS-CoV-2 S1 IgM/ IgA / IgG

AESKULISA® SARS-CoV-2 S1 IgA, IgG, and IgM tests are qualitative and quantitative immunoassays for the detection of human IgM, IgA, and IgG antibodies in serum or plasma directed against SARS-CoV-2 by the highly specific spike protein (S1). The spike protein has the advantage over the nucleocapsid protein that is highly specific for the SARS-CoV-2 virus.

Resulting in a much lower risk of cross-reactions with antibodies against other members of the coronavirus family. IgG antibodies react against the receptor-binding domain (RBD) on the spike proteins. They are considered to be neutralizing and, therefore, suitable for monitoring the antibody titer of patients.

AESKULISA® SARS-CoV-2 S1 IgG Antibodytest (Spike Protein)allows the confirmation of pathogen contact and the determination of the immune status. It can be used to detect and monitor the antibody titer of a patient.

Thanks to all the visitors, partners, and friends who visited us during the 2020 MEDLAB conference. AESKU had our full line of innovative automation platforms on display. We were highlighting our ability to be a complete laboratory solutions provider, helping us expand our business into many new countries. Read more...

It was a successful year for AESKU at this AACC. We announced the 400th placement of our HELIOS All-in-One IFA device, and officially introduced three products - the HELIOS HTC, AESQC IFA, and our own HERA automation management software. Read more...

Tuesday April 10th, 2018, was the official start date for the HELIOS system at the Vicente Corral Moscoso Regional Hospital in the city of Cuenca, Ecuador.

This public-sector hospital has been named ‘number one in service’ in its region.

Its clinical lab performs high-complexity routine, emergency and outpatient testing 24 hours a day, 7 days a week while serving as a reference location for a network of six area labs and the Teofilo Davila de Machala, Isidro Ayora de Loja, and Jose Carrasco Arteaga of the IESS – Cuenca Hospitals. Read more...

AESKU is introducing a new Immunofluorescence Assay (IFA) Quality Control product line – AESQC IFA – that complies with International Consensus on Antinuclear Antibody Patterns (ICAP) nomenclature.

QCs in IFA are not only important as part of assay quality management, but now as IFA readers are becoming standard devices in laboratories, assuring their ability to read patterns in a standardized manner has also become important.

The AESQC IFA product line allows laboratories to compare IFA reader performance to a set of controls validated and standardized to the ICAP nomenclature. Read more...

“The main reason we were looking at the HELIOS was our sheer volume,” said Badley. “We couldn’t afford in our facility to sit around and have one full FTE be dedicated to doing manual IFA, ANA; it just wasn’t feasible. Also, just finding qualified technicians is a very hard thing to do in our area. Having people there that can read ANAs and read those patterns was hard.” Read more...

Since 2014, the Stifterverband acknowledges research companies that embrace their special responsibility for state and society with the "Innovative through Research" seal. Now Aesku.Diagnostics has received the award for its research competence and innovative abilities. Read more...